Skip to content
Homepage
Category:
Press Releases
Posted Date:
June 7, 2026
Can Quetiapine Be Used For Anxiety? Experts Weigh In On Benefits & Side Effects
NewsNetwork
June 7, 2026
HVAC Inspection App Features: Offline Use, GPS, Image Capture & Data Lookup
NewsNetwork
June 7, 2026
Best Hair Growth Serum Ingredients: What Briogeo, Olaplex & Trybello Use
NewsNetwork
June 7, 2026
Milwaukee Battery Cold Weather Use: Tips For Improving Performance
NewsNetwork
June 7, 2026
Best Montessori Toys For 1 Year Olds: What Science Says About Educational Play
NewsNetwork
June 7, 2026
Global Demand for Lithium, Rare Earth Minerals, and EV Technology Continues To Grow
Elektros, Inc.
June 7, 2026
Global Electrification, Critical Minerals and EV Innovation: A Long-Term Vision for Investors Following the Evolution of Lithium, Rare Earths and Emerging Technologies
Elektros, Inc.
June 7, 2026
Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis
Zealand Pharma
June 7, 2026
Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity
Boehringer Ingelheim Limited
June 7, 2026
Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide
Sciwind Biosciences Co., Ltd.
June 7, 2026
Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health
AMERICAN DIABETES ASSOCIATION
June 7, 2026
Investors Worldwide Are Discovering New Opportunities In Lithium, Rare Earth Minerals, and EV Technology
Elektros, Inc.
June 7, 2026
Billionaires, Millionaires, Microcap and Penny Stock Investors: The Global Race for Lithium, Rare Earth Minerals and EV Technology Is Accelerating
Elektros, Inc.
June 7, 2026
Rosen Law Firm Encourages DNOW Inc. Investors to Inquire About Securities Class Action Investigation – DNOW
THE ROSEN LAW FIRM, P. A.
June 7, 2026
Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist
Antag Therapeutics
June 7, 2026
Prev
1
…
2,076
2,077
2,078
